Seeking Alpha

Idera +5% AH on positive IMO-8400 data

  • New preclinical data being presented by Idera (IDRA) demonstrates the ability of the company's IMO-8400 drug to "inhibit the survival and proliferation of B-cell lymphoma cells harboring the oncogenic MYD88 L265P genetic mutation."
  • Idera has opened enrollment for a Phase 1/2 trial to evaluate IMO-8400 for use in treating " patients with Waldenströms macroglobulinemia who are refractory to prior therapies," and expects patient treatment to start in Q2.
  • The company has also submitted a request to the FDA to "conduct a Phase 1/2 trial in patients with [diffuse large B-cell lymphoma] who harbor the MYD88 L265P mutation."
Comments (4)
  • EXPstocktrader
    , contributor
    Comments (388) | Send Message
    Of course this is positive data.


    GL, EXP
    7 Apr, 06:19 PM Reply Like
  • jcri33
    , contributor
    Comments (11) | Send Message
    Excellent data presentation today!!!! we should run well tomorrow from this news release.
    7 Apr, 07:10 PM Reply Like
  • mrbarido
    , contributor
    Comment (1) | Send Message
    Why would this run? Because of a posterboard presentation? I would love to see it run but not sure with the way the market is if that is going to happen. I don't own much (avg. 5+) and would love to see it run, but I don't see it. I guess my glass is half empty. GLTA.
    8 Apr, 09:13 AM Reply Like
  • Sierrastar
    , contributor
    Comment (1) | Send Message
    Macro view IDRA still bullish over last ~8 months:
    - Insider buying
    - GENZ hires '14
    - Baker Brothers investment
    - Baker Brothers on BOD
    - Science
    - Pipeline
    - Trial results, positive data




    Downside - share has been beaten back from near $7 level. Not for faint of heart!
    8 Apr, 03:27 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: